Skip to main content
Premium Trial:

Request an Annual Quote

Celera Launches into Drug Target Sector

SAN FRANCISCO, Jan 10 – Celera Genomics on Wednesday announced moves that signal the beginning of the company's foray into the drug target discovery sector.

"We are looking to identify new drug targets," Peter Chambre, Celera’s chief operating officer, said at a company presentation at the JP Morgan H&Q conference.

As part of that move, Celera also announced on Wednesday that it had hired Stephen Hoffman, a pioneer in the development of DNA vaccines, as its senior vice president of immunotherapeutics.

Hoffman, who was previously director of the United States Navy’s malaria research efforts, will be in charge of a team that will look for novel therapeutic proteins and other molecules for treating an preventing disease. He will also be in charge of developing vaccines.

Cancer would be Hoffman’s first area of focus.

In addition, Chambre said that over the next 12 months Celera would also look to form collaborations with population genetic companies. By doing this, "we see an opportunity to focus on more rapid discovery of disease genes," Chambre said.

He said that Celera’s future discoveries would also be used to build its molecular diagnostics business.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.